Italy's National Strategy Boosts Biotech
Italy is implementing a coordinated national strategy to become a major European biotech hub, focusing on digital infrastructure and public-private partnerships. A recent analysis highlights how Italian CDMOs are leveraging AI to optimize batch consistency and accelerate tech transfer. The initiative is presented as a model for how national policy can accelerate biomanufacturing innovation.
- Italy's National Recovery and Resilience Plan (NRRP) is a key driver of the strategy, allocating approximately €40.32 billion to "Digitization, Innovation, and Competitiveness," which directly supports the modernization of biomanufacturing infrastructure. This funding is intended to accelerate the adoption of digital technologies and bolster the production capacity in strategic sectors, including life sciences. - The venture capital climate is increasingly favorable, with life sciences ranking among the top three most funded industries in Italy. In 2024, the sector raised approximately €300 million, a 60% increase compared to 2023, with biotech and pharma startups being the most funded segments. This trend is supported by specialized funds like the Sofinnova Telethon Fund, the largest in Italy dedicated to biotech, which has made significant early-stage investments in gene therapy companies such as Genespire, Epsilen Bio, and PinCell. - Italian CDMOs are recognized for their investment in high-tech manufacturing, including automation and Industry 4.0 technologies like Process Analytical Technology (PAT) and digitalization. This focus on advanced manufacturing is a key factor in Italy's position as Europe's largest pharmaceutical CDMO market, with an estimated 23% of the continent's output. - There is a pronounced national focus on advanced therapies, with Italy being one of the first European countries to bring such treatments to market. Italian companies have developed 45 advanced therapy products, including somatic cell and gene therapies, with a strong concentration in oncology. This is supported by a robust research ecosystem, including the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget). - Major infrastructure investments are central to the strategy, exemplified by the Human Technopole in Milan, a new national research institute for life sciences. This center is designed to function as a large-scale, centralized research hub, providing the national and international research community with access to cutting-edge facilities for genomics, computational biology, and structural biology, fostering public-private collaboration. - The cell and gene therapy (CGT) manufacturing capacity is rapidly expanding to meet demand. For instance, AGC Biologics has significantly expanded its Milan facility, the first GMP-approved plant in Europe for ex-vivo gene therapy, to increase viral vector production capacity with the addition of new 1,000L single-use bioreactors and a new automated filling line. - The updated Bioeconomy in Italy (BIT II) strategy aims to increase the sector's turnover and employment by 15% by 2030. This strategy emphasizes creating value from local biodiversity, improving coordination between government ministries and regions, and supporting startups through technology transfer hubs. - Digital twin technology is an emerging area of focus for optimizing bioprocesses. Figures like Massimo Morbidelli, a professor at Politecnico di Milano, are pioneering the use of these virtual models to monitor and enhance both the development and manufacturing stages of biopharmaceuticals, promising greater efficiency and consistency.
